Hang Quach

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17